Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 4 25 IN PLASTIC CONTAINER versus INPERSOL ZM W DEXTROSE 2 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 4 25 IN PLASTIC CONTAINER versus INPERSOL ZM W DEXTROSE 2 5 IN PLASTIC CONTAINER.
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER vs INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Removes waste products (e.g., urea, creatinine) and excess electrolytes via diffusion and ultrafiltration across the peritoneal membrane; dextrose acts as osmotic agent to generate ultrafiltration.
Provides osmotic gradient for peritoneal dialysis via hyperosmolar dextrose solution; dextrose is absorbed and metabolized, driving ultrafiltration of excess fluid and solutes across peritoneal membrane.
Intraperitoneal administration: 2 to 2.5 liters per exchange, 4 to 5 exchanges daily, as part of continuous ambulatory peritoneal dialysis (CAPD).
Intraperitoneal administration: 2 liters of 2.5% dextrose solution per exchange, 4 exchanges daily (8 liters total per day) for continuous ambulatory peritoneal dialysis (CAPD).
None Documented
None Documented
Not applicable; dextrose is rapidly metabolized (half-life ~2-5 min), electrolytes are distributed and excreted renally with half-life dependent on renal function.
Not applicable as a continuous dialysis solution; systemic glucose half-life ~1.5-2 hours in normal physiology, but prolonged in renal impairment.
Renal: 100% (electrolytes and dextrose are completely reabsorbed or metabolized; water is excreted renally). Biliary/fecal: 0%.
Renal (predominantly via dialysate effluent); peritoneal dialysis removes glucose and metabolites. Less than 5% metabolized; no significant biliary or fecal excretion.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution